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KEY POINTS
 Clinicopathologic correlation is an essential element in the diagnostic approach to cutaneous
lymphomas.
 Cutaneous lymphomas show overlapping histologic and immunophenotypic features, but can differ
significantly in their course and prognosis.
 Monoclonality does not necessarily indicate malignancy. Lack of monoclonality does not exclude
the diagnosis of cutaneous lymphoma.INTRODUCTION
Primary cutaneous lymphomas (CLs) comprise a
heterogeneous group of lymphocytic neoplasms
with a broad spectrum of clinical, histologic, immu-
nophenotypical, and genetic features (Box 1).1–3
Thehistopathological examinationplaysanessential
role and is often the starting point in the diagnostic
workup of CLs. The classification of CLs follows
the currentWorld Health Organization (WHO) classi-
fication (4th edition, 2008), which is widely accepted
by hematopathologists and dermatopathologists.3
TheWHO classification of the tumors of hematopoi-
etic and lymphoid tissues follows themultiparameter
approach by defining lymphomas according to their
clinical, histopathological, immunophenotypic, and
genetic features as well as the side of primary mani-
festation, which was originally introduced by the
Revised European-American Lymphoma classifica-
tion (REAL).4,5
This aim of this review is to provide an approach
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and to emphasize the impact of clinicopatholog-
ical correlation.
Pathologic Approach
Histopathologically, various growth patterns can be
distinguished. Some are more prevalent in certain
forms of CLs, whereas others are found throughout
theentire spectrumofCLs. Thegrowthpatternsand
cytomorphology provide first diagnostic hints. For
example, epidermotropic infiltrates of small to
medium-sized lymphocytes are most commonly
found in cutaneous T-cell lymphomas (CTCLs),
whereas dense dermal lymphocytic infiltrates, of
variable size and cytomorphology, are commonly
present in cutaneous B-cell lymphomas (CBCLs).
For practical reasons, 6 major patterns can be
distinguished in CLs: epidermotropic, nodular,
diffuse, subcutaneous, angiocentric/angiodes-
tructive, and intravascular. Among each growth
pattern, additional histopathological features mayinterest and no source of funding in the article to
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Box 1
World Health Organization classification for lymphoid neoplasms
MATURE T-CELL AND NK-CELL NEOPLASMS
Mycosis fungoides (MF)
MF variants and subtypes:
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome
Adult T-cell leukemia/lymphoma
Primary cutaneous CD301 T-cell lymphoproliferative disorders
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal NK-/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell lymphoma
Rare subtypes:
 Primary cutaneous CD81 aggressive epidermotropic cytotoxic T-cell lymphoma (provisional)
 Primary cutaneous g/d T-cell lymphoma
 Primary cutaneous CD41 small/medium T-cell lymphoma (provisional entity)
Primary cutaneous peripheral T-cell lymphoma, unspecified
MATURE B-CELL NEOPLASMS
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
Primary cutaneous follicle center lymphoma
Diffuse large B-cell lymphoma, NOS
Primary cutaneous diffuse large B-cell lymphoma, leg type
Primary cutaneous diffuse large B-cell lymphoma, others
Intravascular large B-cell lymphoma
Note: This list is mainly limited to cutaneous lymphomas in the WHO classification.
Data from Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid
tissues. 4th edition. Lyon (France): IARC Press; 2008.
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tropic infiltrates or granulomatous features.
 Epidermotropic infiltrates are most commonly
found in CTCLs, particularly in their initial dis-
ease stage (eg, mycosis fungoides [MF],
patch, and plaque stage), throughout the
entire disease evolution like in Se´zary syn-
drome (SS), or in cutaneous CD81 aggressive
epidermotropic cytotoxic T-cell lymphoma
(AETCL).
 Nodular and diffuse infiltrates are a hallmark of
progressive forms of CTCLs (eg, MF tumor
stage; peripheral T-cell lymphoma [PTCL] un-
specified) as well as CBCLs. The subcutaneous growth pattern is typically
found in subcutaneous lymphomas, including
the subcutaneous panniculitis-like T-cell lym-
phoma (SPTCL)withexpressionofT-cell recep-
tor (TCR) a/b and the subcutaneous form of g/d
T-cell lymphoma,butmay rarelybeobservedas
rare variants in other CTCL and CBCL forms.
 Angiocentric and angiodestructive (ie, an-
gioinvasive) infiltrates are characteristic for
aggressive T- and T-/natural killer (NK)-cell
lymphomas, such as extranodal T-/NK-cell
lymphoma, nasal type, and cutaneous g/d T-
cell lymphoma. Exceptions to the rule are
indolent or low-malignant forms of CD301
T-cell lymphoproliferations as lymphomatoid
Pathologic Diagnosis of Cutaneous Lymphomas 657papulosis (LyP) type E and the angioinvasive
variant of primary cutaneous anaplastic
large-cell lymphoma (PCALCL).
 The intravascular growth pattern is pathog-
nomonic for intravascular T- and B-cell
lymphoma.
Cytomorphologically, small, medium-sized,
and large lymphocytes can be distinguished with
variable degrees of nuclear pleomorphism. In
B-cell lymphomas, small lymphocytes with lym-
phoplasmacytoid differentiation, monozytoid B
cells, as well as tumor cells with centrocyte-like
differentiation can be distinguished from tumor
cells resembling centroblast, immunoblasts, and
plasmablasts. Noteworthy, an immunoblastic dif-
ferentiation can also be seen in some form of
CTCLs, especially in PCALCL, MF tumor stage,
and cutaneous PTCLs, unspecified.
Phenotyping
Immunohistochemistry allows assigning the tumor
cells to distinct subsets of T, B, NK/T, or NK cells,
including their functional subsets (eg, follicular
helper T cells or regulatory T cells). For some forms
of CLs, the phenotypic features represent essential
diagnostic criteria. For example, in SPTCLs, by defi-
nition, the tumor cells require expression of the a/b
chain of the TCR. Certain phenotypic and genetic
markers not only are of diagnostic importance but
also have a prognostic implication (eg, loss of
9p21 in diffuse large B-cell lymphoma, leg-type) or
represent therapeutic targets (eg, CD30, anaplastic
lymphomakinase [ALK]/p80). Thesemarkersshould
be specifically mentioned in the pathology report.
Genotyping
CLs are considered to represent monoclonal pro-
liferation of T or B cells displaying identical rear-
rangement of TCR genes or the genes of the
heavy chain of immunoglobulins (IgH). Therefore,
clonality assays are mostly based on polymerase
chain reaction (PCR) or Southern blot analysis,
which can serve as an adjunctive diagnostic
marker for CLs. It has, however, to be emphasized
that the detection of a clonal T- or B-cell popula-
tion by itself per se is not proving the diagnosis
of lymphoma, because clonal lymphocyte popula-
tions can also be found in a subset of inflammatory
skin disorders like eczematous reactions or lichen-
oid skin disorders.6 Apart from clonality assays,
additional genetic analysis allows the identification
of genetic alterations, which are characteristic for
certain CL entities.
Almost all phenotypic and genetic analyses
can nowadays be examined on archival (ie,formalin-fixed and paraffin-embedded) tissue.
Because a detailed characterization of a lympho-
cytic infiltrate requires analyzing several pheno-
typic factors and, in many cases, also genetic
alterations and clonality studies, biopsies or exci-
sions of sufficient size are mandatory. In practical
terms, a punch biopsy of 4 to 6 mm diameter or
ideally a spindle-shaped excision with an axis
length of 1 cm should be taken and immediately
transferred to buffered 10% formalin at room tem-
perature. Considering the rapid evolution of new
and emerging prognostic and therapeutic
markers, a tissue bank is recommended in which
access to archived tissue is preserved: additional
fresh tissue can be stored in liquid nitrogen
at 80C or transferred to special fixatives that
preserve RNA, DNA, and proteins for future
examinations.
In most cases, the histopathological and the
phenotypic analyses alone are limited to provide
a list of differential diagnoses. As outlined earlier,
CLs display overlapping clinical, histologic, immu-
nophenotypic, and genetic features. As a conse-
quence, clinicopathological correlation is of
utmost importance to achieve the final diagnosis.
Thereby, the terminology should follow the
nomenclature of CLs as given in the current
WHO classification for hematopoietic and
lymphoid tissues to facilitate communication bet-
ween clinicians and pathologists.3
In the following, the diagnostic criteria, the differ-
ential diagnoses, and the impact of immunopheno-
typical and genetic analysis for the diagnostic
workuparediscussed in anentity-basedapproach.CUTANEOUS T-CELL LYMPHOMAS
Mycosis Fungoides
This CTCL accounts for approximately 40% to
50% of all CLs and represents therefore the most
common form. The WHO classification defines
the disease by its classical presentation with an
evolution of 3 stages: patches, plaques, and tu-
mors.1–3 The disease shows a broad spectrum of
clinical, histologic, and phenotypic variants.
Some of these variants do not clinically follow
the classic presentation with patches, plaques,
and tumors, but rather exhibit unusual features
such as the papular variant of MF. The papular
variant, which can also be found in follicular MF
and other rare clinical variants, has not been
considered in the current WHO classification.
Histology
The histologic findings in early MF are subtle, and
therefore, histologic diagnosis is challenging.
There is a perivascular infiltrate in the upper
Kempf & Mitteldorf658dermis, which contains mostly small lymphocytes,
eosinophils, and a few plasma cells. The lympho-
cytes show subtle nuclear atypia and may be ar-
ranged along the junctional zone (lining-up) and
single-cell epidermotropism (Fig. 1). Occasionally,
vacuolization along the junctional zone can be
seen. Pautrier microabscesses, which are a hall-
mark of plaque stage, are found in less than 20%
of the cases in the patch stage.7 In MF plaque
stage, a denser bandlike infiltrate in the upper
and middermis with a prominent epidermotropism
of small to medium-sized atypical lymphocytes
with nuclear pleomorphism and formation of Pau-
trier microabscesses is usually found. MF tumor
stage is characterized by a dense dermal infiltrate
extending into the upper parts of the subcutis,
which is composed of pleomorphic tumor cells of
variable size. Thereby, transformation is defined
by the presence of at least 25% of large tumor
cells. Usually an admixture of eosinophils, plasma
cells, and histiocytes can be seen. Ulceration
commonly occurs. The epidermotropism of tumor
cells, as is seen in patch and plaque stage of MF,
can get lost in tumor stage of the disease.
Immunophenotype and clonality
Various phenotypes can be observed in MF with a
CD41- T-helper phenotype being the most com-
mon one. Other phenotypes include CD81,
CD301, CD561, as well as CD4/CD8-double-
positive or CD4/CD8 double-negative variants.8,9
None of these phenotypes were shown to have a
prognostic impact in MF patch or plaque stage.10
However, cases of early MF with CD30 expression
in early disease stage and a high proliferation rate
particularly in the dermal component of the infil-
trate have been found to be more aggressive in
one study.11 Loss of markers, particularly CD7,
can be observed in MF, but also in inflammatory
dermatosis. Expression of CD7 by less than 10%
of the lymphocytes was proposed as a diagnosticFig. 1. MF, patch stage: epidermotropism of atypical
lymphocytes. HE, 100.criterion for early MF.12 Nevertheless, the loss of
this marker has little diagnostic impact, because
expression of CD7 by less than 10% of the infil-
trating lymphocytes is a rare finding. In addition,
an increased CD4:CD8 ratio (more than 8:1) may
be a hint for MF. Recently, the expression of
thymocyte selection associated HMG-box (TOX)
was found in a high number of early MF lesions
by immunohistochemistry, but is rarely observed
in chronic dermatosis.13 Thus, this marker may
be useful in the distinction, but further studies
are needed to confirm this observation. Some phe-
notypes are more commonly associated with un-
usual clinical features such as CD81 MF, which
often presents with hyperpigmented or hypopig-
mented patches and plaques, whereas CD4/CD8
double-negative phenotype may be associated
with annular lesions.14,15
In tumor stage, loss of T-cell markers may occur
and variable expression of CD30 can be seen.
Expression of CD30 in tumor stage was shown
to be an independent marker for a better
disease-related survival.16 The expression of pro-
grammed cell death 1 (PD-1) can occur in all
stages of MF and is not a helpful marker in the dif-
ferentiation from other forms of CLs.
Because monoclonal rearrangement of TCR
genes can only be found in half of the early MF
cases, clonality studies are of limited value in the
diagnosis of early MF.
Genetics
Inactivation of the CDKN2A-CDKN2B was shown
to be associated with shorter survival in patients
with transformed MF demonstrating deletion of
this locus.17
Differential diagnosis
The history and the clinicopathologic correlation
are essential to distinguish early MF from chronic
eczema, psoriasis, actinic reticulosis, as well as
so-called lymphomatoid drug eruptions and lym-
phomatoid contact dermatitis. Among lym-
phomas, early MF needs to be distinguished from
LyP (type B and D), epidermotropic forms of cuta-
neous g/d T-cell lymphoma, SS, and adult T-cell
lymphoma/leukemia (ATLL). The differential diag-
nosis includes, depending on the cell size of the tu-
mor cells, a primary cutaneousCD4-positive small/
medium-sized T-cell lymphoma (CD41- SMTL),
which, however, clinically usually presents with a
solitary nodule and not with patches and plaques
as MF. Moreover, epidermotropism is only focally
present or entirely absent in CD41- SMTL. The
distinction of MF tumor stage from PCALCL may
be impossible in individual cases on histologic
grounds alone. Recently, the expression of
Pathologic Diagnosis of Cutaneous Lymphomas 6595-hydroxymethylcytosine (5-hMC) was shown to
be a useful marker in the distinction. However,
the most important differentiation criterion is the
presence of patches and plaques preceding the
evolution of tumors in MF, whereas PCALCL
presents with rapidly growing solitary or grouped
nodules without preceding patches and plaques.Variants
Particularly, MF variants linked to an impaired
prognosis deserve special attention. Those vari-
ants include the follicular (synonym folliculotropic)
as well as the granulomatous form of the disease.
Follicular (synonym folliculotropic) MF is charac-
terized by a perifollicular dense infiltrate of mostly
small to medium-sized atypical lymphocytes with
prominent folliculotropism (Fig. 2). Epidermotrop-
ism into the interfollicular epidermis, which is a
useful diagnostic finding for MF, is absent in
40% to 60% of folliculotropic MF.18 The latter
may be accompanied by mucinous degeneration
of the hair follicle epithelia in half of the cases.
Distinction from idiopathic follicular mucinosis is
challenging. The detection of significant nuclear
atypia, an elevated CD4/CD8 ratio, the presence
of numerous CD301- cells, and monoclonal rear-
rangement of TCR genes as well as the clinical fea-
tures with multiple alopecic patches and patches
or papular lesions indicate MF, whereas the occur-
rence of a solitary lesion in a young patient, partic-
ularly in children, and lack of nuclear atypia argue
for idiopathic follicular mucinosis.19 In addition,
other forms of CTCLs such as follicular LyP and
ATLL, which can manifest with folliculotropic infil-
trates and accompanying follicular mucinosis,
have to be distinguished from folliculotropic
MF.20,21 Folliculotropic MF and granulomatous
MF carry an impaired prognosis of approximatelyFig. 2. Follicular MF: folliculotropic infiltrates of small
to medium-sized lymphocytes with nuclear atypia.
Note mucinous degeneration of the hair follicle
epithelium (follicular mucinosis). HE, 200.60% to 70% 5-year survival rate.22,23 Therefore,
the recognition and intense therapy are essential.
Remarkably, the presence of a syringotropic
component, which may accompany folliculotropic
infiltrates or occur exclusively without a folliculo-
tropic component, does not show an impaired
prognosis compared with the classic type of MF.24
ThegranulomatousvariantofMFpresents inmost
cases with sarcoid-like granulomas, occasionally
with granuloma anulare-like features (Fig. 3).25,26
The nuclear atypia of the mostly small lymphocytes
is rather subtle. In addition, epidermotropism is ab-
sent in half of the cases.Distinction fromsarcoidosis
and other granulomatous diseases is challenging
andoften results inadelay indiagnosinggranuloma-
tous MF. Detection of clonal T cells is a useful
adjunctive diagnostic marker to separate granulo-
matous MF from sarcoidosis.27,28
Pagetoid reticulosis is a rare unilesional MF sub-
type presenting with a solitary psoriasiform or
hyperkeratotic lesion often at acral sites.29 Histo-
logically, a prominent epidermotropism and
nuclear pleomorphism of the epidermotropic atyp-
ical lymphocytes are seen. Various phenotypes
have been identified in pagetoid reticulosis. There-
fore, the differential diagnosis is broad and in-
cludes CD41, CD81, CD301, as well as CD561
epidermotropic infiltrates. Pagetoid reticulosis
shows the same excellent prognosis as other
forms of unilesional MF.30
Se´zary Syndrome
This rare CTCL form accounts for 2% to 3% of all
CLs. SS carries the phenotype of central memory
T cells, whereas MF phenotypically corresponds
to effector memory T cells.31 Because the histo-
logic features are nonspecific in up to 40% of the
biopsies, the characteristic clinical presentationFig. 3. Granulomatous MF: sarcoidlike granulomas
with admixture of small lymphocytes with subtle nu-
clear atypia. HE, 100.
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enlarged lymph nodes, and particularly, the detec-
tion of more than a thousand cerebriform large tu-
mor cells per milliliter in the peripheral blood are
crucial for the diagnosis of SS. In addition, the
detection of an identical TCR clone in the skin
and the peripheral blood is a useful criterion.
Despite classicMF andSS representing different
lymphomas, the histologic features are very similar
between SS andMF patch and plaque stage. SS is
histologically characterized in many cases by a
dense bandlike monotonous lymphocytic infiltrate
of small lymphocytes with nuclear atypia (Fig. 4).
The infiltrate appears more monotonous than in
MF. Eosinophils and plasma cells can be admixed.
Epidermotropism with formation of Pautrier micro-
abscesses is found in about 60% of the cases, but
can be completely absent. Moreover, a pretreat-
ment with topical steroids or ultraviolet light may
result in the absence of epidermotropic T cells.
Repeated biopsies are useful to enhance the diag-
nostic accuracy.32,33 Phenotypically, the tumor
cells express CD3, CD4, and often PD-1.34 Howev-
er, as outlined earlier, PD-1 does not allow distin-
guishing SS from other forms of CTCL. The
distinction from other CTCL forms presenting with
erythroderma such as erythrodermic MF and adult
T-cell lymphoma/leukemia requires a history with
patches andplaques inMF and the detection of hu-
man T-lymphotropic virus type 1 (HTLV1)-DNA in-
tegrated into the host genome or serologic
demonstration of HTLV1 infection in ATLL, respec-
tively. The distinction of SS from erythrodermic in-
flammatory dissases (EID) is based on histology
only achieved with certainty in less than 60% of
the cases.35 The clinicopathologic correlation and
the absence of more than 1000 atypical circulating
T cells in the peripheral blood per microliter are
essential to differentiate an SS from an EID such
as atopic dermatitis, psoriasis, pityriasis rubra pila-
ris, and in particular, erythrodermic drug eruption.Fig. 4. SS: perivascular monotonous lymphocytic infil-
trate in the upper dermis. Note absence of epidermo-
tropism in this biopsy. HE, 100.For the distinction of SS and EID, the expression
of CD7, PD-1, and TOX may be helpful. PD-1 was
expressed by more than 50% of the T cells in 16
of 24 (66%) SS cases, but only in 4 of 30 (13%)
EID cases.34 Although loss of CD7 has been
observed in SS as well as in EID, the expression
of CD7 by 20%or less of the T cells in skin biopsies
was limited to SS. Recent data indicate that the
expression of TOX may be an additional marker if
more than 50% of the infiltrating T cells show a
strong expression of TOX in SS, whereas most
cases of EID show only focal and weak expression
of this marker.
Primary Cutaneous CD30-Positive
Lymphoproliferative Disorders
Primary cutaneous CD30-positive lymphoprolifer-
ative disorders represent approximately 20% to
25% of CTCL and comprise a spectrum of lym-
phoproliferations including LyP and PCALCL as
well as so-called borderline lesions.1,36 The com-
mon hallmark of these disorders is the expression
of CD30, a tumor necrosis factor superfamily che-
mokine receptor, by the atypical lymphoid cells.
Lymphomatoid Papulosis
LyP is defined by its characteristic clinical presen-
tation with recurrent papules and small nodules,
which undergo spontaneous regression within a
few weeks to months. Occasionally, varioliform
scars are left behind after regression. The disease
has an excellent prognosis without mortality, but
patients with LyP are at risk to develop a second
lymphoid neoplasm, especially MF, nodal Hodgkin
lymphoma, and PCALCL or systemic anaplastic
large cell lymphoma (ALCL), before the onset of
LyP or during the disease course.
Histology
LyP displays a broad spectrum of histologic man-
ifestations. Five major histologic types can be
distinguished (Table 1)37,38: They differ in regard
to the growth pattern (epidermotropic, nodular,
angioinvasive), the composition of infiltrate (scat-
tered atypical large CD301 cells scattered and ar-
ranged in small clusters vs cohesive sheets), and
the admixture of reactive cells such as neutrophils,
eosinophils, and histiocytes. In all histologic types,
the atypical lymphocytes express T-cell markers
and CD30 except for the histologic type B, charac-
terized by an epidermotropic T-cell infiltrate, which
displays variable expression of CD30 (0%–77%)
by the small to medium-sized lymphocytes
(Fig. 5). In addition to these histologic types A to
E, a follicular, a granulomatous, and a syringo-
tropic variant of LyP have been described.
Table 1
Lymphomatoid papulosis: histologic types and differential diagnosis
LyP Type Histology Differential Diagnosis Distinguishing Criteria
Type A Wedge-shaped infiltrate
Scattered or in small clusters
arranged large
CD301 lymphocytes with
nuclear pleomorphism and
mitotic activity
Background infiltrate of
histiocytes, eosinophils,
neutrophils
 Hodgkin lymphoma
(primary or secondary
cutaneous)
 MF (transformation)
Staging examination (in nodal
HL)
Patches and plaques in MF vs
self-regressing
papulonodular lesions in LyP
Type B Epidermotropic infiltrate of
small to medium-sized
lymphocytes with atypical
chromatin-dense nuclei and
variable expression of CD30
(0%–77%)
 MF (patch/plaque stage)
 Cutaneous g/d lymphoma
(epidermotropic)
Patches and plaques in MF vs
self-regressing
papulonodular lesions in LyP
Multiple plaques with erosions
IHC: Expression of TCR g
Type C Nodular cohesive infiltrate of
large CD301 pleomorphic or
anaplastic lymphocytes with
abundant cytoplasm and
mitotic activity
Admixture of only few
eosinophils and neutrophils
 Anaplastic large-cell
lymphoma (primary
cutaneous or systemic
form)
 MF (transformation)
 PTCL, NOS (primary
cutaneous or nodal)
 Adult T-cell lymphoma/
leukemia
Clinical presentation with
solitary or grouped nodules
in PCALCL. Staging
examinations in sALCL.
Patches and plaques preceding
tumors in MF
Lack of CD30 or expression by
only a minority of tumor
cells, staging examinations
Integration of HTLV-1/2 in
tumor cell genome
Type D Epidermotropism of atypical
small to medium-sized
pleomorphic lymphocytes
with expression of CD8 and
CD30
Deep dermal or subcutaneous
perivascular infiltrates may
be present
 Pagetoid reticulosis
 Primary cutaneous
aggressive
epidermotropic
CD81 cytotoxic T-cell
lymphoma
 Cutaneous g/d lymphoma
Unilesional erythematous
scaling lesion in pagetoid
reticulosis
Multiple rapidly evolving
plaques and nodules with
erosions and necrosis
Lack of CD30 expression
Multiple plaques with erosions
IHC: Expression of TCR g
Type E Angioinvasive (ie, angiocentric
and angiodestructive)
infiltrates of mostly small to
medium-sized pleomorphic
CD301 lymphocytes and
expression of CD81 in 70%
of the cases. Admixture of
eosinophils.
Vascular occlusion by atypical
lymphocytes or thrombi,
hemorrhage, extensive
necrosis, and ulceration.
 Extranodal NK-/T-cell
lymphoma, nasal type
 Cutaneous g/d lymphoma
 Anaplastic large-cell
lymphoma (primary
cutaneous or systemic
form) with angiocentric
and angiodestructive
growth
Association with EBV, mostly
secondary cutaneous
involvement (staging)
IHC: Expression of TCR g
Clinical presentation with
solitary or grouped nodules
in PCALCL. Staging
examinations in sALCL.
Abbreviations: HL, hodgkin lymphoma; HTLV-1/2, human T-lymphotropic virus type 1/2; IHC, immunohistochemistry;
sALCL, systemic anaplastic large-cell lymphoma.
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Fig. 5. LyP: epidermotropic infiltrates of small to
medium-sized lymphocytes in type B. HE, 100.
Table 2
CD8-positive epidermotropic infiltrates
MF, CD81
phenotype
Hypopigmented and
hyperpigmented patches/
plaques, lining-up, and
exocytosis of small
lymphocytes with nuclear
Kempf & Mitteldorf662Furthermore, recent genetic studies revealed the
presence of IRF4/DUSPP rearrangements on
chromosome 6p25.3 in a subset of LyP, which his-
tologically presents with typical histologic findings
(ie, an epidermotropic component of atypical small
lymphocytes) and, in addition, a dense dermal
nodular infiltrate of medium-sized to large atypical
CD301 lymphocytes.39atypia; CD45R0, CD301/,
T-cell clone1
CD81 AETCL Rapidly evolving erosive or
ulcerated patches, plaques,
and nodules.
Epidermotropism of small to
medium-sized atypical
lymphocytes, apoptotic
keratinocytes; CD45RA1,
CD30
LyP type D Recurrent papules and small
nodules with spontaneous
regression.
Epidermotropism of small to
medium-sized atypical
lymphocytes; CD81 (100%),
CD301 (90%).
Drug eruption Maculopapular rash, activated
lymphocytes with subtle
nuclear atypia; CD81, CD30
Pityriasis
lichenoides
Papular rash with collerette-
like desquamation,
vacuolization in the
junctional zone, exocytosis
of small lymphocytes,
apoptotic keratinocytes,
focal hyperparakeratosis
with inclusion of
neutrophils; CD41 or CD81,
CD30/1
Note: Clonal T cells may also be detected in pityriasis
lichenoides (up to 60%) and drug eruption. Thus, detec-
tion of a clonal T-cell population is not a useful marker
to differentiate between the listed disorders.Differential diagnosis
Eachof thehistologic typesofLyPhas itsdifferential
diagnoses (see Table 1). Several infectious and in-
flammatory skin disorders have been shown to oc-
casionally harbor medium-sized to large CD301
activated lymphocytes and thus may resemble
LyP type A. Detection of clusters of atypical
CD301 cells, the detection of a T-cell clone, and
the characteristic clinical presentation allow distin-
guishing these disorders from LyP type A in most
cases.40,41 LyP type B has to be differentiated
from MF, especially because CD30 expression by
the epidermotropic lymphocytes can be absent in
LyP type B and, on the other hand, MF may show
expression of CD30 by epidermotropic lympho-
cytes even in early disease stage. The clinical pre-
sentation, however, allows differentiation between
MF (patches, plaques) and LyP (papules and small
nodules). A combination of both features within
the same lesion has been referred to as persistent
agminated LyP. LyP type C resembles the findings
in primary cutaneous or systemic ALCL as well as
transformed MF. The distinction of those disorders
has to rely on clinicopathologic correlation demon-
strating patches and plaques in MF and rapidly
growing solitary or grouped tumors in ALCL, in
contrast to LyP presenting with recurrent papules
and small nodules. The distinction of LyP type D
from primary cutaneous CD81 AETCL relies on the
clinical presentation with rapidly evolving erosive
and ulcerated patches, plaques, and nodules inthe latter (Table 2).42 Moreover, expression of
CD30 has not been observed in CD81 AETCL. The
distinction of LyP type D from pityriasis lichenoides
et variolaformis acuta (PLEVA) with expression of
CD8 and CD30 by the intraepidermal cells may be
very challenging in individual cases, especially
because clinicopathologic correlation does not
allow distinguishing the 2 disorders in all patients.
LyP type E needs to be distinguished from the an-
gioinvasive formof ALCL aswell as fromaggressive
T-cell lymphomas with angiodestructive and an-
gioinvasive growth, such as extranodal NK T-cell
lymphoma and nasal type, by the presence of
Epstein-Barr virus (EBV) in the latter and cutaneous
g/d T-cell lymphoma by the clinical presentation as
well as the expression of TCR g or d43 (Table 3).
Table 3
Angiocentric and angiodestructive
(angioinvasive) lymphocytic infiltrates
Extranodal
NK-/T-cell
lymphoma,
nasal type
Ulcerated plaques and
nodules
Dermal and subcutaneous
infiltrates of medium-
sized atypical
lymphocytes; CD3ε1
CD561, CD30/1, EBER1
Cutaneous
g/d T-cell
lymphoma
Erosive or ulcerated
plaques and nodules.
Dermal and
subcutaneous,
occasionally
epidermotropic
infiltrates of atypical
lymphocytes with
variable size; CD31
CD561, CD30/1, EBER
PTCL, unspecified Plaques or nodules
Dermal and occasionally
subcutaneous infiltrates
of variably sized atypical
lymphocytes
CD3, EBER
LyP type E
(angioinvasive
type)
Recurrent papules and
small nodules evolving
to ulcers (1–4 cm) with
spontaneous regression
Dermal and occasionally
subcutaneous infiltrates
of medium-sized
lymphocytes CD31, CD81
(70%), CD301 (100%)
Primary cutaneous
anaplastic
large-cell
lymphoma,
angioinvasive
type
Solitary or grouped tumors
with ulceration.
Histology and
phenotype identical to
LyP type E.
Pathologic Diagnosis of Cutaneous Lymphomas 663Primary Cutaneous Anaplastic Large T-Cell
Lymphoma
In most patients, PCALCL presents with rapidly
growing solitary or grouped and often ulcerated tu-
mors (Fig. 6). Histologically, in the vast majority of
the cases, a dense nodular cohesive infiltrate of
large pleomorphic, anaplastic, or immunoblastic
T cells is found (Fig. 7). Morphologic variants
include neutrophil-rich, histiocyte-rich, and sarco-
matoid and angioinvasive forms (Fig. 8).44–46
Neutrophil-rich PCALCL is more commonly seen
in immunocompromised patients. By definition,
more than 75%of the cells expressCD30. Remark-
ably, often a weak expression of CD3 or the
absence of CD3 expression can be seen. Various
phenotypes have been identified with CD41
T-helper phenotype being the most common one.
The phenotype does not have a prognostic impact.
In contrast to nodal or systemic ALCL, almost all
cases of PCALCL are negative for ALK1 and the
underlying translocation t(2;5).47 Nevertheless,
rare cases of ALK-positive PCALCL have been
documented.48 Recently, genetic analysis re-
vealed the presence of IRF4/DUSP22 rearrange-
ments on chromosome 6p25.3 in approximately a
third of PCALCL, but not in systemic ALCL. The
detection of this translocation by fluorescence in
situ hybridization (FISH) represents a useful
method in the diagnostic workup of ALCL.49 It
must, however, be emphasized that certain cases
of LyP may carry the same rearrangement, and
thus, IRF4/DUSP22 rearrangement is not specific
for PCALCL. Differential diagnosis includes LyP
type C, which can be only distinguished with cer-
tainty by clinicopathologic correlation and tumor
stage of MF, which occasionally shows expression
of CD30 bymost tumor cells. The clinicopathologic
correlation with patches and plaques in MF pa-
tients allows distinction from PCALCL.Fig. 6. PCALCL: ulcerated tumor on the left cheek.
Fig. 7. PCALCL: dense cohesive sheets of anaplastic
lymphoid cells. Note mitotic activity. HE, 200.
Fig. 8. PCALCL: angioinvasive form with angiocentric
and angiodestructive infiltrates of medium-sized to
large tumor cells permeating the vessel wall. HE,200.
Kempf & Mitteldorf664Subcutaneous Panniculitis-Like T-Cell
Lymphoma
Despite the fact that SPTCL is a rare lymphoma
and accounts for only 1% of all CLs, it represents
the vast majority of all subcutaneous forms of
T-cell lymphomas (75%). According to the WHO
classification, SPTCL is by definition restricted
to cases expressing a TCR a/b phenotype.1,3
Therefore, the immunohistochemical demonstra-
tion of the expression of TCR a/b (ie, positivity
for b-F1) is the essential diagnostic marker for
this entity.
Histology
SPTCL is characterized by a predominantly lobular
lymphocytic infiltrate composed of small to
medium-sized tumor cells with nuclear pleomor-
phism.50 The tumor cells surround lipocytes (so-
called rimming). One has to be aware that the
rimming of lipocytes, however, is not disease-
specific and can be observed in other forms of
subcutaneous lymphomas and inflammatory dis-
orders, such as lupus panniculitis. Karyorrhexis
and cytophagocytosis may be observed.
Immunophenotype and clonality
Tumor cells in SPTCL express CD31, CD4,
CD81, CD56, TIA 11, granzyme B1, and as the
most important marker, b-F11. There is no associ-
ation with epstein-barr virus (EBV) infection. Clonal
T cells are found in up to 80% of the cases.
Differential diagnosis
Immunophenotyping is essential to differentiate
SPTCL from a subcutaneous form of g/d T-cell
lymphoma, which expresses the g/d chain of
TCR. The latter can be demonstrated on archival
tissue by immunohistochemical detection of TCR
g or on frozen tissue by immunohistochemical
detection of TCR d. In addition, subcutaneousg/d lymphoma expresses CD56. In contrast to ex-
tranodal T-/NK-cell lymphoma, which may also
present with subcutaneous involvement, subcu-
taneous g/d T-cell lymphoma is not associated
with EBV. In extranodal T-/NK-cell lymphoma,
however, EBV-encoded small RNAs (EBER) can
be demonstrated by in situ hybridization. Among
nonlymphomatous infiltrates, lupus panniculitis is
the major differential diagnosis of SPTCL. Both
entities show overlapping histologic features
with predominantly lobular lymphocytic infiltrates.
In both entities, plasma cells can be
observed.51,52 Useful histopathological criteria
for distinguishing lupus panniculitis from SPLTCL
include epidermal changes, lymphoid follicles
with reactive germinal centers, clusters of B cells,
and mixed cell infiltrate with prominent plasma
cells in lupus panniculitis.53 In addition, clusters
of CD1231 plasmacytoid dendritic cells are found
in lupus panniculitis. Nevertheless, the distinction
can be impossible in individual cases. Some au-
thors have suggested that both entities may
belong to a spectrum of disease, because lupus
panniculitis and SPTCL may occur in the same in-
dividual. Furthermore, borreliosis manifesting with
lobular panniculitis represents a diagnostic pitfall,
because the high number of CD81 lymphocytes
mimics SPTCL, and the plasma cells as well as
mucin deposition and clusters of CD1231 plas-
macytoid dendritic cells are similar to that seen
in lupus panniculitis.54
Cutaneous Peripheral T-Cell Lymphoma
PTCL comprise a group of rare subtypes including
primary cutaneous CD41 small/medium-sized
lymphoma, primary cutaneous CD81 aggressive
epidermotropic T-cell lymphoma, as well as cuta-
neous g/d T-cell lymphoma. For those cases that
do not fit into one of these rare subtypes or any
other well-defined CTCL entity, the term cuta-
neous PTCL unspecified (PTCL NOS) can be
applied or used.1,55
Cutaneous CD41- Small/Medium-Sized T-Cell
Lymphoma
This lymphoproliferative process is listed as a pro-
visional entity in the current WHO classification.
Originally considered to be a rare lymphoma
form, this lymphoproliferation is nowadays more
commonly diagnosed. In most patients, the dis-
ease presents clinically with a solitary nodule on
the head or neck (Fig. 9).
Histologically, a dense nodular infiltrate
composed of small to medium-sized lymphocytes
with chromatin dense nuclei and a slight nuclear
pleomorphism with admixture of eosinophils,
Fig. 11. Cutaneous CD4-positive SMTL: infiltrate of
small to medium-sized lymphocytes with slight nuclear
pleomorphism. HE, 200.
Fig. 9. Cutaneous CD4-positive SMTL: nonulcerated
solitary nodule on the right temple.
Pathologic Diagnosis of Cutaneous Lymphomas 665plasma cells, and other B cells as well as histio-
cytes are found (Fig. 10). The small to medium-
sized lymphocytes express CD4 and a subset of
the CD41 cells also express PD-1 (Fig. 11).56
The expression of PD-1, however, is not restricted
to CD41SMTL, but can be found in various stages
of MF, SS, as well as other CTCLs. Therefore, PD-
1 cannot be considered a diagnostic marker spe-
cific for CD41SMTL, and additional markers,
such as bcl-6, ICOS, CXCL-13, or CD10, need to
be expressed by the tumor cells to prove a follic-
ular helper T phenotype. The proliferation rate usu-
ally does not extend more than 30%.34,57 In about
60% of the cases, a clonal T-cell population can
be detected.57 Because of this relatively low
detection rate, the value of clonality studies in
CD41 SMTL is limited.
Differential diagnosis includes tumor stageofMF,
which can be distinguished by the presence of
patches and plaques preceding the developmentFig. 10. Cutaneous CD4-positive SMTL: nodular
dermal lymphocytic infiltrate without epidermotrop-
ism. HE, 2.5.of nodular lesions (Table 4). Secondary cutaneous
involvement by angioimmunoblastic T-cell lym-
phoma is based on the results of staging examina-
tions and additional laboratory findings. Infiltrates
of cutaneousmarginal zone (MZL) B-cell lymphoma
have tobeconsideredparticularly if therearemono-
typic plasma cells present. The most challenging
differential diagnosis is nodular T-cell pseudolym-
phoma due to overlapping histologic and pheno-
typic findings. In 5% of the patients, the
development of nodular T-cell pseudolymphoma
is linked to drug intake, particularly of antiepileptics.
The prognosis of CD41 SMTL in its solitary or
localized form is excellent with a 5-year survival
rate greater than 95%. Patients with multiple le-
sions, however, and a higher proliferation rate of
tumor cells as well as a lower number of infiltrating
CD81 cells carry an impaired prognosis and
should be treated more aggressively.58 In regard
to the overlapping features, some authors
consider CD41 SMTL and nodular T-cell pseudo-
lymphoma to represent one disease and therefore
refer to the process as primary cutaneous CD41
small/medium-sized lymphoproliferative disorder
to underline its indolent course. Considering the
impaired prognosis of CD41 SMTL presenting
with multifocal lesions, this constellation should
rather be referred to as PTCL NOS.
Primary Cutaneous CD81 Aggressive
Epidermotropic Cytotoxic T-Cell Lymphoma
This lymphoma is a very rare, but highly aggres-
sive form of CTCL characterized by widespread
erosive patches, plaques, papules, and nodules
with necrosis and ulceration.59,60 Men are more
commonly affected. Usually the patients are in
their fifth to seventh decade at diagnosis. Diag-
nostic criteria for CD81 AECTCL include short
Table 4
Nodular infiltrates of small/medium-sized atypical T cells
CD41 SMTL Mostly solitary nodules on the head and neck; admixture of B
cells.
Expression of follicular helper T-cell markers (eg, PD-1, bcl-6,
ICOS). Admixture of B cells (in clusters) and plasma cells.
Transformed MF Patches and plaques
Often admixture of large pleomorphic lymphocytes; variable
expression of CD30 and PD-1.
Angioimmunoblastic T-cell lymphoma Often multiple lesions.
Admixture of Bcells and plasma cells.
Expression of follicular helper T-cell markers. Association with
EBV (in 50% of the skin infiltrates).
Nodular T-cell pseudolymphoma Identical clinical and histologic as well as phenotypic findings
as in CD41 SMTL.
Kempf & Mitteldorf666history, widespread lesions, epidermotropism of
pleomorphic T cells, a CD81/CD4 phenotype,
and an aggressive course as essential diagnostic
elements.61 Histologically, this lymphoma entity is
characterized by an epidermotropic infiltrate of
small to medium-sized to even large atypical lym-
phocytes with pleomorphic chromatin dense
nuclei (Fig. 12). Commonly, apoptotic keratino-
cytes, spongiosis, intraepidermal vesicles, and
blister formation as well as epidermal necrosis
can be seen. In addition to the epidermotropic
component, a deeper component involving the
dermis and subcutis and presenting occasionally
with angioinvasive growth can be observed. Phe-
notyping is crucial for the diagnosis of this lym-
phoma entity because the tumor cells express a
characteristic phenotype (CD31e, CD41, CD81,
CD30, CD45RA1, CD45RO, TIA11, and b F11)
(Fig. 13). There is no association with EBV.
The differential diagnosis of CD81 AECTCL is
broad and includes primarily CD81 MF (SeeFig. 12. CutaneousCD8-positiveAETCL:epidermotropic
infiltrates of atypical lymphocytes. Note apoptotic kera-
tinocytes. HE,200.Table 2). The latter, however, presents with nonul-
cerated and nonerosive patches and plaques and
shows an indolent course in contrast to CD81
AECTCL. In addition, usually there is no significant
number of apoptotic keratinocytes. In addition,
LyP type D must be considered, which differs from
CD81 AECTCL by the expression of CD30 (in 90%
of the cases) and the lack of expression of
CD45RA. Moreover and most importantly, LyP
type D shows recurrent papulonodular lesions
with spontaneous regression and exhibits an indo-
lent course.Asadifferential diagnosisamong the in-
flammatory disorders, CD81, CD301PLEVAcan be
distinguishedby the lackof nuclear atypia as is seen
in CD81 AECTCL. Moreover, the clinical presenta-
tion differs significantly from CD81 AECTCL.Cutaneous g/d T-Cell Lymphoma
This rare and aggressive lymphoma is character-
ized by a clonal proliferation of mature andFig. 13. Cutaneous CD8-positive AETCL: expression of
CD8 by the epidermotropic atypical lymphocytes.
Immunohistochemistry, 200
Pathologic Diagnosis of Cutaneous Lymphomas 667activated g/d T cells. Histologically, epidermo-
tropic (pagetoid), dermal diffuse, or nodular or
subcutaneous infiltrates or a combination of these
patterns can be found.50,62 In particular, the sub-
cutaneous form of g/d T-cell lymphoma is often
accompanied by a dermal and an epidermotropic
component. In the subcutaneous form, a lobular
infiltrate of medium-sized to large cells with
chromatin-dense atypical nuclei is present. Angio-
centric and angiodestructive infiltrates are com-
mon features.63 The tumor cells exhibit a CD21,
CD31, CD561 phenotype being often CD4/CD8-
double-negative. In addition, cytotoxic molecules
(TIA1, granzyme B, and perforin) are typically ex-
pressed. By definition, the tumor cells lack expres-
sion of TCR a/b (b F1), but express TCR g/d, which
can be demonstrated by the expression of TCR g
on formalin-fixed, paraffin-embedded sections or
by TCR d on fresh frozen tissue. Clonality studies
reveal a clonal rearrangement of TCR g/d. The
vast majority of cutaneous g/d lymphoma is not
associated with EBV, but rare cases of EBV1 pri-
mary cutaneous gamma/delta T-cell lymphoma
(PCGD-TCL) have been reported. Cutaneous g/d
T-cell lymphoma can be accompanied by a hemo-
phagocytic syndrome defined by fever, spleno-
megaly, cytopenia, hypertriglyceridemia, or
hypofibrinogenemia, elevated serum ferritin,
CD251 cells, and the evidence of hemophagocytic
histiocytosis in bone marrow, spleen, or lymph
nodes.
Differential diagnosis includes the epidermo-
tropic form of PCGD-TCL MF (plaque stage).
Because classic MF cases with expression of
TCR g/d have been documented in the literature,
the definite distinction between MF and PCGD-
TCL requires, however, careful clinicopathologic
correlation and should not only be based on the
phenotype of the tumor cells.64 In the presence
of predominantly dermal infiltrates in PCGD-TCL
with angiocentric features, other aggressive forms
of T-cell lymphomas with angiocentric/angiodes-
tructive infiltrates need to be considered. In this
context, one has to be aware that distinction
from extranodal NK-/T-cell lymphoma, nasal type
may be very challenging, because this lymphoma
and PCGD-TCL show overlapping histologic as
well phenotypic features. The presence of EBV
highlighted by in situ hybridization rather argues
for extranodal NK-/T-cell lymphoma, nasal type.Cutaneous Peripheral T-Cell Lymphoma,
Unspecified
PTCL NOS is a very rare form of CTCL that is in
most cases associated with an aggressive course.
Patients usually present with rapidly growing largesolitary ulcerated tumors or disseminated nodular
lesions without preceding patches and plaques.
Histologically, in most cases diffuse or nodular
dense infiltrates of mostly medium to large-sized
lymphocytic tumor cells with significant nuclear
pleomorphism are found.65,66 Epidermotropism is
found in a subset of cases. An angiocentric
component can be present. Eosinophils of variable
numbers and plasma cells are admixed. Variable
T-cell phenotypes (CD41 or CD81 or CD4/CD8-
double-negative and -double-positive) with or
without expression of cytotoxic proteins are
found.66–68 By definition, most tumor cells do not
express CD30.1 An aberrant expression of CD20,
but not additional B-cell markers, can be observed
in a subset of cases. Clonal rearrangement can be
detected, but is often not required for diagnostic
purposes.
The differential diagnosis includes primarily
transformed MF, which differs from PCTL NOS
by preceding patches and plaques (Table 5).
Importantly, radiologic staging examinations
have to exclude secondary cutaneous involve-
ment by a nodal PTCL NOS. Primary cutaneous
or systemic ALCL is distinguished by the expres-
sion of CD30 by at least 75% of tumor cells. The
differentiation from extranodal NK-/T-cell lym-
phoma and g/d T-cell lymphoma is primarily based
on the phenotype (EBV-positivity) in extranodal
NK-/T-cell lymphoma and expression of TCR g/
d in PCGD-TCL. Adult T-cell leukemia/lymphoma
shows an association with HTLV1, which is not
present in PCTL NOS.Extranodal Natural Killer-/T-Cell Lymphoma,
Nasal Type
This rare, but aggressive form of lymphoma is
characterized phenotypically by a phenotype
resembling NK/T cells and NK cells. Hydroa
vacciniformia-like lymphoma represents a variant
of EBV1 NK-/T-cell lymphoma occurring mostly
in Central and South America in young adults
and children.69,70 Facial or periorbital edema is
typically found. Skin lesions further include blister
formation and ulcerations, particularly on sun-
exposed areas.
The histology shows predominantly angiocen-
tric and angiodestructive infiltrates of tumor cells
of variable size with nuclear pleomorphism and
mitotic activity. Usually numerous eosinophils,
plasma cells, and histiocytes can be observed.
Phenotypically, the tumor cells lack expression of
surface CD3, but express CD3ε, CD56, and cyto-
toxic markers.71,72 Most importantly, EBV can be
demonstrated by in situ hybridization or
immunohistochemistry.
Table 5
Large T-cell lymphoid infiltrates: differential diagnoses
Cutaneous anaplastic large cell lymphoma Solitary or grouped ulcerated nodule or nodules.
Expression of CD30 by more than 75% of the
tumor cells.
LyP (type C) Recurrent papules and nodules.
Expression of CD30 by the large atypical
lymphocytes.
MF, transformation Patches, plaques (and tumors).
Presence of more than 25% of large pleomorphic
cells with variable expression of CD30. Variable
loss of T-cell markers. Admixture of B cells
possible.
Primary cutaneous peripheral T-cell lymphoma,
unspecified
Solitary or multiple nodules/tumors. Variable
phenotype (cytotoxic vs noncytotoxic, CD4 vs
CD8 or double-negative); expression of CD30
by <30% of the cells.
Extranodal NK-/T-cell lymphoma, nasal type Ulcerated tumors.
Angiocentric and angiodestructive growth.
Expression of CD3ε1, CD561, EBER1.
Cutaneous g/d-T-cell lymphoma Erosive or ulcerated plaques and tumors.
Expression of CD31 CD81 TCRg1 EBER.
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Cutaneous B-cell lymphomas are the secondmost
common group of CLs, accounting for about 25%
to 35% of all CLs.73Primary Cutaneous Marginal Zone Lymphoma
In the WHO classification, primary cutaneous mar-
ginal zone lymphoma (PCMZL) belongs to the
group of extranodal MZL of mucosa-associated
lymphoid tissue (MALT-lymphoma).74,75 Recent
data indicate that PCMZL differs from other
MALT-lymphoma with regard to the expression
of class-switched immunoglobulins, chemokine
receptors, translocations, and associated infec-
tions.76,77 In the WHO-EORTC (European Organi-
zation For Research and Treatment of Cancer)
classification and WHO classification, cutaneous
immunocytoma, and primary cutaneous plasmo-
cytoma are considered to represent variants of
PCMZL.1,78 These variants are characterized by
a dense dermal infiltrate, which is almost entirely
composed of plasma cells with monotypic expres-
sion of Ig light chains.1,78 A systemic manifestation
has to be excluded by staging procedures. An
overview of the diagnostic characteristics is given
in Table 6.
Histology
PCMZL is characterized by a nodular dermal lym-
phocytic infiltrate, separated from the uninvolved
epidermis by a grenz zone and sometimesextending into the subcutaneous fat (Fig. 14).
The infiltrate consists of small lymphocytes, lym-
phoplasmacytoid cells, and plasma cells, which
are commonly located in the edge of the infiltrates
and next to the epidermis (Fig. 15). Reactive
germinal centers can be seen. The infiltrate is typi-
cally accompanied by abundant admixed T
lymphocytes.
Morphologic variants of PCMZL are reported
with (i) marked plasmacytoid differentiation,79 (ii)
a high number of admixed T lymphocytes,79 (iii) a
predominance of monocytoid B cells instead of
lymphoplasmocytoid cells. A blastic transforma-
tion is a rare event in PCMZL and has been linked
to an aggressive clinical course. Because of a re-
ported CD5 and CD23 expression,80 these lesions
have to be differentiated from B-cell chronic lym-
phocytic leukemia (B-CLL) with large cell transfor-
mation (so-called Richter transformation).81
Two subtypes of PCMZL have been described
based on different expression profiles of immuno-
globulins76,77: (i) the more common class-switch
form, which predominantly consists of a nodular
and perivascular infiltrate with numerous admixed
T cells. The plasma cells express IgG, IgA, or IgE.
An IgD expression is found in reactive lymph folli-
cles. The B cells lack CXCR3; (ii) the rare non-
class-switch form, which presents with larger
nodular dermal infiltrates predominantly
composed of B cells. The number of admixed T
cells is only moderate. The plasma cells express
IgM. The CXCR3 expression is strong in T and
Table 6
Cutaneous B-cell lymphomas
Cutaneous Marginal Zone
Lymphoma
Cutaneous Follicle Center
Lymphoma
Diffuse Large B-Cell Lymphoma,
Leg Type
Diffuse Large B-Cell Lymphoma,
Other
Pattern Nodular, geographic Nodular, diffuse Diffuse Diffuse
Infiltrate
composition
Small lymphocytes,
lymphoplasmocytoid cells,
plasma cells
Predominantly centrocytes Predominantly centroblasts and
immunoblasts
Predominantly centroblasts and
immunoblasts
Follicular
structures
Reactive GC (bcl61, bcl2) In follicular growth pattern:
neoplastic follicles (bcl61,
bcl2/1)
No germinal centers No germinal centers
Phenoytpe CD20/CD79a/PAX51
bcl21, bcl6
k, l
CD20/CD79a/PAX51
bcl2, bcl61, MUM-1, IgM,
irregular networks of FDC
(CD211/CD351)
CD20/CD79a/PAX51
bcl211, bcl6/1, MUM-11,
IgM1, lack of FDC networks
(CD21/CD35)
CD20/CD79a/PAX51
bcl2, bcl61, MUM-11/, IgM,
FOX-P1 1/ lack of FDC
networks (CD21/CD35)
Genetics t(14;18)(q32;q21)IGH/BCL2 and
t(14;18) (q32,q21) IGH/MALT
translocation is an indicator for
transformation toward higher-
grade B-cell lymphoma.
t(14;18) translocation was found
in up to 50%. This translocation
was not linked to differences in
clinical presentation and
prognosis. Deletion of
chromosome 14q32.33 has
been reported.
Translocations involving MYC,
BCL6, IGH genes. High levels of
DNA amplifications of
18q21.31-q21.33, including
BCL2 and MALT genes. Loss of
9p21 is a negative prognostic
marker. Chromosomal
imbalances with gains in 18q
and 7p and loss of 6q.
Abbreviation: GC, germinal centers.
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Fig. 14. Cutaneous MZL: dermal and superficial subcu-
taneous nodular and confluent lympohcytic infiltrate.
Note the grenz zone beneath the epidermis. HE, 2.5.
Fig. 16. Cutaneous MZL: expression of bcl-2 by tumor
cells. Note the spared reactivegerminal centers. HE,5.
Kempf & Mitteldorf670mild in B cells. In the non-class-switched form, ex-
tracutaneous involvement is more often observed.
In contrast to noncutaneous MZL, IgG4 expres-
sion is found in approximately 40% of PCMZL and
may represent a marker for PCMZL.82
Immunophenotype and clonality
The tumor cells express CD20, CD79a, and bcl-2
and are negative for bcl-6, CD5, CD10, and
CD43 (Fig. 16).1,83 Plasma cells could be high-
lighted by CD138. To detect monotypic plasma
cells, immunohistochemistry or in situ hybridiza-
tion must be performed. Most experts consider
monoclonal a ratio of 5:1 or 10:1. Monotypic
plasma cells can be found in 85% of the cases84:
in two-thirds of cases, kappa is predominant,84
and a heavy chain rearrangement is detected in
about 60% to 70% of the cases.84
Genetics
t(14;18) (q32;q21) IGH/BCL2 and t(14;18)
(q32;q21) IGH/MALT-1 were seen in cases ofFig. 15. Cutaneous MZL: proliferation of small lym-
phocytes in the interfollicular component and reac-
tive germinal centers. HE, 200.PCMZL with transformation toward higher-grade
B-cell lymphoma.85
Differential diagnosis
Distinction of PCMZL from cutaneous B-cell pseu-
dolymphoma (B-PSL), which shows similar fea-
tures as PCMZL with small B cells, plasma cells,
and reactivegerminal centers, isbasedalsoonclin-
ical presentation (mostly solitary lesion in B-PSL,
characteristic predilection sites of ears, scrotum,
and nipples in Borrelia-associated B-PSL [Syno-
nym Borrelia-associated lymphocytoma cutis]
and a polytypic expression of Ig light chains in
B-PSL). In primary cutaneous follicle center cell
lymphoma (PCFCL), the tumor cells show a
centrocyte-like differentiation. Plasma cells are
usually sparse or absent in PCFCL. Cutaneous
involvement by B-cell chronic lymphocytic leuke-
mia (B-CLL) may sometimes simulate PCMZL and
could be differentiated by their immunohistochem-
ical profiles. In contrast to PCMZL, the tumor cells
in B-CLL express CD5, CD23, and CD43.83,86
Another diagnostic pitfall is a secondary cutaneous
infiltrate of extracutaneous MALT lymphoma,
which must be excluded by staging procedures. It
remains a matter of debate whether PCMZL repre-
sents a de novo neoplastic process or whether B-
PSL and PCMZL represent different evolutionary
steps of the samedisease. Therefore, a clear differ-
entiation between both entities could be difficult or
impossible in individual cases. Monotypic plasma
cells or a monoclonal IgH rearrangement (same
clone in repeated assays) argues for a PCMZL. In
certain areas of Europe, PCMZL is rarely associ-
ated with Borrelia burgdorferi infection, but this
link has not been found in PCMZL from Asia and
the United States.87–89
In plasma cell predominate variants (primary
cutaneous plasmocytoma, immunocytoma), other
differential diagnoses have to be considered.
Pathologic Diagnosis of Cutaneous Lymphomas 671Secondary cutaneous plasmocytoma could be
excluded by staging procedures. Rare, but impor-
tant differential diagnoses are vegetating herpes
virus infections in HIV patients,90 lymphoplasma-
cytoid plaque,91,92 and cutaneous plasmocyto-
sis.93 These entities can show a plasma cell–rich
infiltrate, but the plasma cells are polyclonal in
contrast to most cases of PCMZL.Primary Cutaneous Follicle Center Lymphoma
PCFCL is listed as a separate entity in the WHO
classification.74 It is characterized by a tumor of
neoplastic follicle centers and is predominantly
composed of centrocyte-like cells. It occurs typi-
cally on the scalp, large tumors of PCFCL on the
back that had been originally referred to as reticu-
lohistiocytoma dorsi (Crosti lymphoma). Miliary
and agminated types of PCFCL can be chal-
lenging, histologically and clinically.94 The diag-
nostic criteria are given in Table 6.
Histology
Threegrowthpatternscanbediscerned, but in all of
them, a proliferation of tumor cells with centrocyte-
like differentiation predominates (Fig. 17):
i. The follicular growth pattern is characterized by
predominantly large neoplastic follicles, which
are composed of centrocyte-like cells. Tingible
body macrophages are only rarely found (less
than 10%).
ii. The diffuse growth pattern is defined by diffuse
aggregates of medium and large centrocytes
with admixed small lymphocytes. Follicular
structures cannot be detected.
iii. In the mixed growth pattern, areas with diffuse
arrangement of centrocyte-like cells, next to
areaswith follicular structures, canbeobserved.Fig. 17. Cutaneous follicle center lymphoma:prolifera-
tion of tumor cells with centrocyte-like differentiation.
HE, 200.As a morphologic variant of PCFCL, a spindle
cell differentiation has been described.95
Cases with coexpression of CD30 or with
blastic transformation can cause diagnostic
difficulties.96,97
Immunophenotype and clonality
The tumor cells in PCFCL express CD20, CD79a,
PAX-5, and bcl-6. They are predominantly nega-
tive for bcl-2 (90%), in contrast to nodal follicular
lymphoma.98 The presence of bcl-2 expression
or t(14; 18) translocation in PCFCL is not linked
to differences in clinical presentation or prog-
nosis.1 Proliferating cells (Ki-671 or MIB-11) are
scattered throughout the entire infiltrate. CD21
highlights large irregular networks of follicular den-
dritic cells (FDC). FOX-P1 expression is an indica-
tor for a worse prognosis.99 A heavy chain
rearrangement could be detected in about 90%
of the cases (BIOMED-2 protocol).100
Genetics
In nodal follicular lymphoma, t(14;18) translocation
is presented in approximately 90% of cases. In
PCFCL t(14;18), translocation was found in up to
50%, but was not linked to differences in clinical
presentation and prognosis.1,98 Deletion of chro-
mosome 14q32.33 has been reported.
Differential diagnosis
Some B-PSLs show features accounting for a sig-
nificant overlap with PCFCL.101,102 In those cases,
coalescing lymphoid follicles with nonpolarized
germinal centers lacking mantle zones and
smudged infiltrate of lymphoid cells spreading
into collagen (often as single cell files), smooth
muscle, vessel walls, and peripheral nerve sheets
may result in diagnostic challenge and mimic
PCFCL. In cases with germinal centers, in B-PSL
the proliferative activity (Ki-671 or MIB-11) and
bcl-6 expression are more restricted to the
germinal centers. Tingible body macrophages
are more often found in B-PSL.103 The networks
of CD21-positive FDCs are more sharply restricted
to the germinal centers.
Comparing CBCL, recent publications have
demonstrated that PD-1 expression is significantly
higher in PCMZL and PCFCL in contrast to primary
cutaneous diffuse large B-cell lymphoma-leg type
(PCDLBCL-LT) and showed PD-1-positive cells
forming so-called pseudorosettes or clusters.
The tumor cells themselves were negative for
PD-1.34,104 Moreover, clusters of CD123-positive
plasmocytoid dendritic cells have been described,
which are found in only a minority of PCFCL and
are absent in PCDLBCL-LT.105
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neous infiltrates of nodal follicular lymphoma,
which often show expression of bcl-2, requires
staging. Secondary cutaneous involvement of
mantle cell lymphoma has to be considered in
the differential diagnosis. The diffuse infiltrates
are composed of blasts and centrocyte-like tumor
cells. The tumor cells are positive for CD5 and cy-
clin D1, but negative for CD23.106
Primary Cutaneous Diffuse Large B-Cell
Lymphoma-Leg Type
PCDLBCL is characterized by dense nodular or
diffuse infiltrates predominated by centroblast-
like and immunoblast-like tumor cells with
noncleaved, round nuclei.1 The PCDLBCL-LT rep-
resents the most common type of diffuse large
B-cell lympoma (DLBCL) and is listed as a distinct
subtype of DLBCL in the current WHO classifica-
tion.3 The diagnostic criteria are outlined in
Table 6.
Histology
There is a diffuse dermal infiltrate of centroblast-
like and immunoblast-like cells with mitotic activity
and only a few admixed reactive lymphocytes
(Fig. 18). Epidermal involvement is uncommon
and rarely described. Usually a subepidermal
grenz zone can be found. An infiltration in the sub-
cutis can be observed. An uncommon histologic
presentation includes a spindle cell and an
anaplastic variant.107 Moreover, an angiocentric
infiltrate108 and expression of CD30 have been
described.109,110
Immunophenotype and clonality
The tumor cells are positive for CD20, CD79a, and
PAX-5 and show a strong expression for bcl-2 andFig. 18. Cutaneous diffuse large B-cell lymphoma, leg
type: cohesive sheets of blasts resembling centroblasts
and immunoblasts. HE, 200.multiple myeloma oncogene-1 (MUM-1). In most
cases, they are negative for bcl-6 and CD10 or
show only a weak expression.111 IgM expression
was identified as an additional adjunctive diag-
nostic marker, which is found in all cases of
DLBCL-LT but only rarely in PCFCL (9%).112 Net-
works of CD21-positive FDC are not found. FOX-
P1 expression was linked to a worse prognosis.99
A diagnostic pitfall may result from CD30
expression in large B-cell lymphoma mimicking
ALCL, but expression of CD20 and absence of T-
cell markers led to the diagnosis.109,110 PD-1
expression is significantly lower in PCDLBCL-LT
than in PCMZL and PCFCL.34,104 The tumor cells
are predominantly negative for PD-1, but in some
cases an expression of PD-1 in the tumor cells
can be observed.34,104 There may be detection
of heavy chain rearrangement by PCR.
Genetics
Genetic analysis has revealed chromosomal loss
of 9p21, which encodes p16 as a negative prog-
nostic marker in PCDLCBL-LT.113 Loss of p16 as-
sessed by immunohistochemistry, however, does
not correlate with these findings, indicating the ne-
cessity for genetic analysis by reverse transcrip-
tion–PCR or FISH analysis. Recurrent deletions in
9p21 (p14 [ARF]/p16 [INK4a/CDKN2A]) have
been found to be a constant finding in
PCDLBCL-LT, whereas PCFCL does not exhibit
this change.114 Chromosomal imbalances have
been identified in up to 85% of PCDLCBL-LT,
with gains in 18q and 7p and loss of 6q as the
most common findings.115,116 A high prevalence
of MYD88L265P mutation shows an association
with a shorter survival.117
Differential diagnosis
Secondary cutaneous involvement has to be
excluded by staging procedures. The most impor-
tant differential diagnosis of PCDLBCL-LT is
PCFCL with a diffuse growth pattern. The tumor
cells of PCFCL are predominantly negative for
bcl-2 and positive for bcl-6 and CD10. Networks
of FDCs cannot be found in the vast majority of
PCDLBCL-LT. IgM expression has been identified
as an additional adjunctive diagnostic marker,
which is found in all cases of PCDLBCL-LT but
only rarely in PCFCL (9%).112 In sharp contrast
to PCDLBCL-LT, the tumor cells of PCDLBCL-
other express bcl-6 in all cases and are negative
for bcl-2.
Primary Cutaneous Diffuse Large B-Cell
Lymphoma-Other
The term PCDLBCL-other refers to cases of large
B-cell lymphomas not belonging to PCDLBCL-
Pathologic Diagnosis of Cutaneous Lymphomas 673LT.1 PCDLBCL-other is a very rare and still poorly
characterized form of DLBCL that shares
cytologic features with PCDLBCL-LT. Histologi-
cally, PCDLBCL-other presents with a diffuse
infiltrate of centroblast-like and immunoblast-like
cells with mitotic activity. Occasionally, numerous
small lymphocytes in addition to the large
centroblast-like and immunoblast-like tumor
cells may be present. Anaplastic, plasmablastic,
and T-cell/histiocyte-rich variants have been
described.1 The tumor cells express bcl-6 in all
cases and are negative for bcl-2. Expression of
MUM-1 is found in 67%. FOX-P1 is positive in
50% of the cases.99 In sharp contrast to
PCDLBCL-LT, the tumor cells of PCDLBCL-
other express bcl-6 in all cases and are negative
for bcl-2.99 Secondary cutaneous involvement
by nodal DLBCL has to be excluded by staging
procedures.Intravascular Large B-Cell Lymphoma
Intravascular large B-cell lymphoma is a rare form
of extranodal large B-cell lymphoma. As the desig-
nation implies, intravascular large B-cell lym-
phoma is characterized by the intravascular
growth of large B cells, especially in small vessels,
particularly capillaries and venules (Fig. 19).118 A
defect in homing receptors on tumor cells
(CD29 5 b1 Integrin; CD54 5 ICAM1) is consid-
ered to be responsible for the unique intravascular
growth pattern.119 Any organ can be involved,
although lymph nodes are usually spared. A sys-
temic form and a cutaneous form are distin-
guished. Histology of skin lesions shows small
dermal and subcutaneous vessels filled with large
B cells with pleomorphic, moderately chromatin
dense nuclei and abundant cytoplasm. Occasion-
ally, tumor cells colonize in hemangiomas.120,121Fig. 19. Intravascular large B-cell lymphoma: accumu-
lation of blasts within small vessels in the subcutis. HE,
200.The tumor cells express CD20 and bcl-2 and
may be positive for CD5 or CD10.
Differential diagnosis includes other forms of
intravascular lymphomas and reactive intralym-
phatic accumulations of lymphocytes. A rare
T-cell and NK cell variant of intravascular lym-
phomas has been described and is associated
in some cases with EBV.122 Iacobelli and col-
leagues123 reported a case of intravascular
ALCL restricted to the skin. The T-cell and
NK-cell variant is not included as a distinct entity
or subtype in the current WHO classification. Dif-
ferential diagnosis includes intralymphatic histio-
cytosis as it can be seen after orthopedic metal
implantation.124 Benign intravascular CD301
T-cell proliferation occurring after trauma or as
a consequence of inflammatory skin diseases
has to be differentiated from the rare T-cell
variant of intravascular lymphoma.125,126 The
distinction could be easily made by immuno-
histochemistry.Epstein-Barr Virus–Associated B-Cell
Lymphoproliferations
EBV is a g-herpes virus, which is associated with a
range of lymphoproliferative disorders. Among the
increasing spectrum of EBV-associated B-cell
lymphoproliferations, EBV-positive DLBCL of the
elderly, plasmablastic lymphoma, EBV-positive
mucocutaneous ulcer, lymphomatoid granuloma-
tosis posttransplant, and methotrexate (MTX)-
associated B-cell lymphoproliferative diseases
are of particular dermatopathologic interest.127
An overview of the diagnostic characteristics of
EBV-associated lymphoproliferations in the skin
is given in Table 7.
EBV-positive DLBCL of the elderly is an EBV-
positive B-cell lymphoma that occurs in patients
older than 50 years of age (with a median age of
71 years) and without any known immunodefi-
ciency or previous lymphoma (see Table 7).128
Nevertheless, the immunologic deterioration or
senescence in immunity as part of the aging pro-
cess is assumed to play a pathogenetic role in
the development of this lymphoma, which involves
most commonly extranodal sites (70%), especially
skin, lung, tonsil, and stomach. The primary cuta-
neous form is very rare.
Plasmablastic lymphoma is a rare variant of
DLBCL that almost exclusively develops in the
setting of HIV infection or other immune defi-
ciencies, including posttransplant.129,130 Risk fac-
tors for the development of the lymphoma in the
setting of organ transplantation include younger
age, higher rejection frequency, and high-dose
cyclosporine therapy.
Table 7
Overview of the diagnostic characteristics of Epstein-Barr virus–associated lymphoproliferations in the skin
EBV-Positive DLBCL of
the Elderly
EBV-Positive
Mucocutaneous Ulcer
MTX-Associated
B-Cell
Lymphoproliferative
Disease
Posttransplant
Lymphoproliferative
Disorder
Plasmablastic
Lymphoma
Lymphomatoid
Granulomatosis
Histology Diffuse infiltrate of
immunoblast-like
or plasmablast-like
cells. Intermingled
tingible body
macrophages.
Geographic
necrosis.
Ulceration.
Polymorphous
infiltrate, mixture
of lymphocytes and
immunoblasts.
Often Hodgkin-/
Reed-Sternberg-like
cell morphology.
Dispersed apoptotic
cells. Abundant
small T cells in the
background.
Scattered plasma
cells, histiocytes,
and eosinophils.
“Cartwheel”
nuclear appearance
of plasma cells.
Angio-invasion
with associated
thrombosis may be
found.
Diffuse infiltrate of
centroblasts and
immunoblasts.
Some
polymorphous
tumor cells with a
Reed-Sternberg-like
appearance.
Admixed T cells. The
EBV-cases were
more
monomorphous
with either
centrocytes or
immunoblasts.
Dense diffuse or
nodular
monomorphous
infiltrates of
centroblastic,
immunoblastic, or
plasmablastic cells.
Often numerous
mitotic figures.
Diffuse or
multinodular
proliferation.
Immunoblast-like
cells or markedly
atypical cells with
plasmablastic
differentiation.
Eccentric nucleus
with a “clock-
faced” chromatin, a
discrete perinuclear
hof and abundant
cytoplasm.
Multinucleated
forms can be
observed.
Numerous/atypical
mitotic figures.
Skin involvement
found in 40%–50%
of the cases.
Patchy infiltration of
the dermis and
subcutis, only little
or no epidermal
involvement.
Angiocentric
lymphohistiocytic
infiltrate with
lymphocytic angiitis
and admixed
atypical B cells.
Multifocal areas of
necrosis.
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Phenotype CD201,CD79a1, PAX-
51, MUM-1/IRF41,
CD10, bcl-6,
CD301/,
light chain
restriction 1/,
Ki-67/MIB-1111
CD3011, CD20(1/),
CD451 (56%),
CD151 (43%),
PAX-51, Oct-21,
MUM-11, CD10,
bcl61/ (focal)
CD20(1), PAX51,
CD79a(1), MUM-11
(80%), FOXP11
(70%), bcl-21
(80%), bcl-6 (70%),
CD301 (60%).
Reduced expression
of B-cell markers in
EBV1 cases.
CD201 or CD79a,
MUM-11, Ki-67/
MIB-1111
CD20, PAX-5-,
CD381 CD1381,
VS38c1, CD101/,
CD79a1/,
CD301/, CD561/
Predominating CD3/
CD41
T-cell infiltrate with
scattered atypical
CD201 B cells.
Viruses In situ hybridization
for EBER. Some
cases also show
expression of latent
membrane protein
1 and EBNA-2.
The CD301 B cells
were positive for
EBER.
EBER is positive in
50% of the cases.
EBV detection (in situ
hybridization or
PCR) in 90% of the
cases.
EBV has been
demostrated in
most cases. EBER
transcripts often
found in virtually all
tumor cells.
HHV-8 has also been
implicated in this
lymphoma type.
Association with EBV
was found in most
cases with EBER
transcripts present
in B cells.
Abbreviations: EBNA-2, epstein barr virus nuclear antigen-2; HHV-8, human herpesvirus 8.
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Kempf & Mitteldorf676Lymphomatoid granulomatosis is a rare B-cell
proliferation with primarily extranodal involvement,
affecting the lungs, skin, central nervous system,
and kidneys. The skin is secondarily involved in
20% to 50% of patients with lymphomatoid gran-
ulomatosis.131 Histologically, angiocentric infil-
trates with large atypical B cells are found in a
background of a dense infiltrate of reactive T cells,
histiocytes, and plasma cells.132,133 Association
with EBV is found in most of the cases with
EBER transcripts present in B cells.
EBV-positive mucocutaneous ulcer is a recently
described B-cell lymphoproliferative disease that
manifests with isolated sharply demarcated ulcer-
ation most commonly in the oropharynx, skin, and
gastrointestinal tract (see Table 7).134 One-third of
the affected patients have a drug-related immuno-
suppression, but age-related immune suppression
is also a feature.134,135 Polymorphous infiltrates of
atypical large B-cell blasts, often with Hodgkin or
Reed-Sternberg cell-like morphology in the back-
ground of abundant small T cells and eosinophils,
are found. The large cells express CD20 and CD30
and are positive for EBER.134
Posttransplant B-cell lymphoproliferative disor-
ders represent a spectrum of lymphoid tissue dis-
ease, ranging from early lesions, such as
plasmacytic hyperplasia, to monomorphic
neoplasm.136 They usually manifest years after
transplantation, are frequently EBV linked, and are
associated with a favorable clinical outcome.136
Methotrexate-associated B-cell lymphoprolifer-
ative disease presents with ulcerating or general-
ized skin lesions. Histologically, it shares features
with PCDLBCL-LT.137 In cases with a reduced
staining for CD79a and marked tumor cell poly-
morphism, this diagnosis should be taken into
account.SUMMARY
Considering the overlap in clinical presentation
and histologic as well as phenotypic features of
CLs, the final diagnosis in cutaneous lymphoproli-
ferative disorders must be based on a multiparam-
eter approach integrating clinicopathologic
correlation and detailed phenotypic studies. Mo-
lecular studies are indicated in selected cases,
but will most probably become more important in
the near future to identify prognostic factors and
therapeutic targets.REFERENCES
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